Newron Pharmaceuticals S.p.A. (0QOI) is a Medical pharmaceuticals company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Newron Pharmaceuticals S.p.A. in 2026. The next earnings report is expected on September 22, 2026.
Next earnings date
22 Sep 2026
In 33 days
EPS estimate
-0.70
Revenue estimate
4.6M
Past earnings
No dividend history available.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Newron Pharmaceuticals S.p.A. (0QOI) is scheduled to report earnings on September 22, 2026.
Newron Pharmaceuticals S.p.A. (0QOI) last reported earnings on March 24, 2026.
Newron Pharmaceuticals S.p.A. (0QOI) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.